Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products
An article in MHRA's monthly Drug Safety Update bulletin.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Letters and medicine recalls sent to healthcare professionals in October 2023
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices: 13 to 17 November 2023
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 6 to 10 November 2023
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 30 October to 3 November 2023
A weekly index of the field safety notices manufacturers issued that week.
MedSafetyWeek November 2023: your Yellow Card report helps to improve patient safety
An article in MHRA's monthly Drug Safety Update bulletin.
Valproate: dispense full packs of valproate-containing medicines
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in September 2023
A periodic index page listing other alerts and letters, not a single alert.
Isotretinoin (Roaccutane▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices: 23 to 27 October 2023
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 16 to 20 October 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Sandoz Limited, Zinacef powder for solution for injection or infusion vials (all strengths, including stock in GSK livery), EL (23)A/38
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 9 to 13 October 2023
A weekly index of the field safety notices manufacturers issued that week.
SteriFeed Colostrum Collection device and risk of choking due to infant airway occlusion, DSI/2023/010
Field Safety Notices: 25 to 29 September 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Max Remedies Ltd, Max Healthcare Paracetamol 500 mg Capsules, EL (23)A/37
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Letters and medicine recalls sent to healthcare professionals in August 2023
A periodic index page listing other alerts and letters, not a single alert.
Fluoroquinolone antibiotics: suicidal thoughts and behaviour
An article in MHRA's monthly Drug Safety Update bulletin.
Statins: very infrequent reports of myasthenia gravis
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices: 18 to 22 September 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Chiesi Ltd., Trimbow 87/5/9 mcg pressurised inhalation solution, EL(23)A/36
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Field Safety Notices: 11 to 15 September 2023
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 4 to 8 September 2023
A weekly index of the field safety notices manufacturers issued that week.
Company led medicines recall: Sun Pharma UK Ltd, Gemcitabine 10mg/ml Solution for Infusion PL 31750/0062 (Single dose Infusion bag, 2000mg/200ml), CLMR(23)A/06
A recall the marketing authorisation holder initiated, published by MHRA.
Class 4 Medicines Defect Information: Colgate-Palmolive (U.K.) Limited, Duraphat 5000ppm Fluoride Toothpaste (51g), EL (23)A/35
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices (FSNs) from 28 August to 1 September 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Theramex HQ UK Ltd, Evorel Sequi, EL (23)A/34
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
No-React® cardiovascular bioprosthesis implantables: discontinuation of CE marking and manufacture. Remaining stock may continue to be used and any adverse incidents reported nationally (DSI/2023/009)
Device Safety Information (DSI): MHRA advice on a device already in use.
Class 4 Medicines Defect Information: Kyowa Kirin Limited, Tostran (Testosterone, 2% gel), EL (23)A/33
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices (FSNs) from 21 to 25 August 2023
A weekly index of the field safety notices manufacturers issued that week.
Letters and medicine recalls sent to healthcare professionals in July 2023
A periodic index page listing other alerts and letters, not a single alert.
Valproate: re-analysis of study on risks in children of men taking valproate
An article in MHRA's monthly Drug Safety Update bulletin.
Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects
An article in MHRA's monthly Drug Safety Update bulletin.
Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
An article in MHRA's monthly Drug Safety Update bulletin.
Class 2 Medicines Recall: Veriton Pharma Limited, Epistatus 2.5 mg oromucosal solution, pre-filled syringe (PFS), EL(23)A/32
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
National Patient Safety Alert: Medical beds, trolleys, bed rails, bed grab handles and lateral turning devices: risk of death from entrapment or falls (NatPSA/2023/010/MHRA)
A National Patient Safety Alert requires named actions from NHS providers.
Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Loceryl 5% w/v Medicated Nail Lacquer (5.0 ml), EL (23)A/31
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices (FSNs) from 14 to 18 August 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Notification, Accord Healthcare Limited, UK, Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion, EL (23)A/30
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Notification, Accord Healthcare Limited, UK, Olmesartan Medoxomil 10mg film coated tablets, EL (23)A/29
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Ethypharm Aurum pre-filled syringes are incompatible with some manufactured needle-free connectors: risk of delay in administering potentially lifesaving medication, DSI/2023/008
Field Safety Notices: 7 August to 11 August 2023
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 31 July to 4 August 2023
A weekly index of the field safety notices manufacturers issued that week.
EyeCee One and EyeCee One Crystal preloaded intraocular lenses (IOLs): update of previous quarantine advice after identification of likely cause, DSI/2023/007
Field Safety Notices: 24 to 28 July 2023
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: B. Braun Medical Ltd, Various Products, EL(23)A/27
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 17 to 21 July 2023
A weekly index of the field safety notices manufacturers issued that week.
Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia
An article in MHRA's monthly Drug Safety Update bulletin.
Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in June 2023
A periodic index page listing other alerts and letters, not a single alert.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.